{"id":"https://openalex.org/W4361945803","doi":"https://doi.org/10.1158/1078-0432.c.6525279","title":"Data from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600\u2013Mutant Solid Tumors","display_name":"Data from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600\u2013Mutant Solid Tumors","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361945803","doi":"https://doi.org/10.1158/1078-0432.c.6525279"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6525279","doi":"https://doi.org/10.1158/1078-0432.c.6525279","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6525279","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.c.6525279","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053119598","display_name":"Clinton Yam","orcid":"https://orcid.org/0000-0002-0809-0851","observed_orcids":["https://orcid.org/0000-0002-0809-0851"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Clinton Yam","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110634","display_name":"Xiaowei Xu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaowei Xu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048327749","display_name":"Michael A. Davies","orcid":"https://orcid.org/0000-0002-0977-0912","observed_orcids":["https://orcid.org/0000-0002-0977-0912"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael A. Davies","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013962604","display_name":"Phyllis A. Gimotty","orcid":"https://orcid.org/0000-0002-3850-9799","observed_orcids":["https://orcid.org/0000-0002-3850-9799"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Phyllis A. Gimotty","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029451307","display_name":"Jennifer J. D. Morrissette","orcid":"https://orcid.org/0000-0001-9460-7177","observed_orcids":["https://orcid.org/0000-0001-9460-7177"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer J.D. Morrissette","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067831105","display_name":"Michael T. Tetzlaff","orcid":"https://orcid.org/0000-0001-7899-4138","observed_orcids":["https://orcid.org/0000-0001-7899-4138"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael T. Tetzlaff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032190194","display_name":"Khalida Wani","orcid":"https://orcid.org/0000-0002-2383-3908","observed_orcids":["https://orcid.org/0000-0002-2383-3908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Khalida M. Wani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049905250","display_name":"Shujing Liu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shujing Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112904352","display_name":"Wanleng Deng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wanleng Deng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079515662","display_name":"Meghan E. Buckley","orcid":"https://orcid.org/0000-0002-3140-6543","observed_orcids":["https://orcid.org/0000-0002-3140-6543"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Meghan Buckley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100308605","display_name":"Jianhua Zhao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jianhua Zhao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009482043","display_name":"Ravi K. Amaravadi","orcid":"https://orcid.org/0000-0002-5768-2474","observed_orcids":["https://orcid.org/0000-0002-5768-2474"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ravi K. Amaravadi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046123003","display_name":"Naomi Balzer Haas","orcid":"https://orcid.org/0000-0001-8907-7968","observed_orcids":["https://orcid.org/0000-0001-8907-7968"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Naomi B. Haas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012911914","display_name":"Ragini Reiney Kudchadkar","orcid":"https://orcid.org/0009-0007-1703-7845","observed_orcids":["https://orcid.org/0009-0007-1703-7845","https://orcid.org/0000-0001-9070-5052"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ragini R. Kudchadkar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056507476","display_name":"Anna C. Pavlick","orcid":"https://orcid.org/0000-0001-7088-0742","observed_orcids":["https://orcid.org/0000-0001-7088-0742"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna C. Pavlick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075566772","display_name":"Jeffrey Alan Sosman","orcid":"https://orcid.org/0000-0002-0650-9698","observed_orcids":["https://orcid.org/0000-0002-0650-9698"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey A. Sosman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056045921","display_name":"Hussein Abdul-Hassan Tawbi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hussein Tawbi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111718738","display_name":"Luke N. Walker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Luke Walker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012671311","display_name":"Lynn Mara Schuchter","orcid":"https://orcid.org/0000-0002-0523-4346","observed_orcids":["https://orcid.org/0000-0002-0523-4346"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lynn M. Schuchter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035929126","display_name":"Giorgos Constantine Karakousis","orcid":"https://orcid.org/0000-0002-9321-2795","observed_orcids":["https://orcid.org/0000-0002-9321-2795"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Giorgos C. Karakousis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5109331981","display_name":"Tara C. Gangadhar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tara C. Gangadhar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9340999722480774,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9340999722480774,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.012000000104308128,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.008700000122189522,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/px-866","display_name":"PX-866","score":0.9990000128746033},{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.9660000205039978},{"id":"https://openalex.org/keywords/pi3k-inhibition","display_name":"PI3K inhibition","score":0.8320000171661377},{"id":"https://openalex.org/keywords/braf-v600-mutation","display_name":"BRAF V600 mutation","score":0.9100000262260437},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.6309999823570251},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8619999885559082},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8040000200271606},{"id":"https://openalex.org/keywords/pten-loss","display_name":"PTEN loss","score":0.7730000019073486},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8880000114440918},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.7829999923706055},{"id":"https://openalex.org/keywords/cd8-t-cell-infiltration","display_name":"CD8+ T cell infiltration","score":0.9909999966621399},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.6340000033378601},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.45399999618530273}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.8199098110198975},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7602658271789551},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6015542149543762},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.5834089517593384},{"id":"https://openalex.org/C2777609662","wikidata":"https://www.wikidata.org/wiki/Q416356","display_name":"PTEN","level":4,"score":0.5794793963432312},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5086551308631897},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.45108893513679504},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4224960505962372},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3770947754383087},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3005322217941284},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.22585687041282654},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.16844990849494934},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.095489501953125},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.07758459448814392},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.c.6525279","doi":"https://doi.org/10.1158/1078-0432.c.6525279","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6525279","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.c.6525279.v1","doi":"https://doi.org/10.1158/1078-0432.c.6525279.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6525279.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6525279","doi":"https://doi.org/10.1158/1078-0432.c.6525279","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6525279","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2765981427","https://openalex.org/W2279741805","https://openalex.org/W2037578452","https://openalex.org/W2531168802","https://openalex.org/W2467921046","https://openalex.org/W2600188869","https://openalex.org/W2289997218","https://openalex.org/W2248535555","https://openalex.org/W2333228607","https://openalex.org/W2531555720"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"The":[2,81],"objectives":[3],"of":[4,12,70,95,102,170,223],"the":[5,10],"study":[6,41],"were":[7,79,87,106,157],"to":[8,23,230,233,244],"evaluate":[9],"safety":[11],"daily":[13,20],"oral":[14],"PX-866":[15,50,71,205,242],"in":[16,42,57,108,153,195,217,249],"combination":[17,58,218],"with":[18,44,59,161,189,202,219,236,241],"twice":[19,118,130,227],"vemurafenib":[21,115,127,224],"and":[22,65,99,120,147,178,239],"identify":[24],"potential":[25],"predictive":[26],"biomarkers":[27],"for":[28,73],"this":[29],"novel":[30],"combination.":[31],"Experimental":[32],"Design:":[33],"We":[34],"conducted":[35],"a":[36,54,63,220],"phase":[37],"I,":[38],"open-label,":[39],"dose-escalation":[40],"patients":[43,78,188],"advanced":[45],"BRAF":[46],"V600\u2013mutant":[47],"solid":[48],"tumors.":[49],"was":[51,206],"administered":[52],"on":[53],"continuous":[55],"schedule":[56],"vemurafenib.":[60],"Patients":[61,163],"underwent":[62],"baseline":[64],"on-treatment":[66],"biopsy":[67],"after":[68],"1-week":[69],"monotherapy":[72],"biomarker":[74],"assessment.":[75],"Results:":[76],"Twenty-four":[77],"enrolled.":[80],"most":[82],"common":[83],"treatment-related":[84],"adverse":[85],"events":[86],"gastrointestinal":[88],"side":[89],"effects.":[90],"One":[91],"dose-limiting":[92],"toxicity":[93],"(DLT)":[94],"grade":[96,103],"3":[97,104,122],"rash":[98],"one":[100],"DLT":[101],"pancreatitis":[105],"observed":[107,158],"cohort":[109,121],"2":[110],"(PX-866":[111,123],"6":[112],"mg":[113,117,125,129,226],"daily;":[114,126],"960":[116,128],"daily)":[119],"8":[124],"daily),":[131],"respectively.":[132],"Of":[133],"23":[134],"response-evaluable":[135],"patients,":[136],"seven":[137],"had":[138,144,149,167,192],"confirmed":[139],"partial":[140],"responses":[141],"(PR),":[142],"10":[143],"stable":[145],"disease,":[146],"six":[148],"disease":[150],"progression.":[151],"Decreases":[152],"intratumoral":[154,196],"pAKT":[155],"expression":[156],"following":[159,200],"treatment":[160,201,231,240],"PX-866.":[162,203],"who":[164],"achieved":[165],"PRs":[166,191],"higher":[168],"rates":[169],"PTEN":[171,180,237],"loss":[172,238],"by":[173],"IHC":[174],"(80%":[175],"vs.":[176,185],"58%)":[177],"pathogenic":[179],"mutations":[181],"and/or":[182],"deletions":[183],"(57%":[184],"25%).":[186],"Two":[187],"durable":[190],"an":[193],"increase":[194,245],"CD8+":[197,246],"T-cell":[198,247],"infiltration":[199,248],"Conclusions:":[204],"well":[207],"tolerated":[208,212],"at":[209],"its":[210],"maximum":[211],"single-agent":[213],"dose":[214,222],"when":[215],"given":[216],"modified":[221],"(720":[225],"daily).":[228],"Response":[229],"appeared":[232],"be":[234],"associated":[235],"seemed":[243],"some":[250],"patients.":[251],"Clin":[252],"Cancer":[253],"Res;":[254],"24(1);":[255],"22\u201332.":[256],"\u00a92017":[257],"AACR.":[258]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}